Vantia's pipeline includes clinical development programmes in the areas of urology and women’s health. Fedovapagon (formerly known as VA106483) has completed multiple phase 1 and 2 studies and is currently being investigated in a pivotal study for the treatment of nocturia, or rising at night to urinate. VA111913 is in development for the treatment of dysmenorrhoea, or painful periods. Both conditions affect large numbers of people and are poorly served by limited treatment options. As a result, Vantia believes both indications represent billion dollar markets.
Vantia's pipeline draws on the Company's expertise in small molecule drug discovery and development. Both development products were discovered by Vantia scientists and have been progressed through pre-clinical development and early clinical studies. Fedovapagon has completed its preclinical safety testing and is supported by a robust package of studies to support drug substance and product manufacturing. These activities have enabled an extensive clinical program including phase 1 studies and phase 2 patient dose ranging studies. Based upon the data generated to date, in combination with regulatory agency discussions, Vantia has initiated and recently completed a clinical study which showed statistically significant effects on multiple endpoints. Vantia intends to conduct a further pivotal trial using the same population and endpoints to support regulatory applications.
The Company's products are protected by a comprehensive intellectual property portfolio comprising 20 patent families.